PSMA6 and susceptibility to pneumonia measurement: Koenecke et al. (2021) investigated this hypothesis through a cohort study based primarily on US claims databases, comparing alpha-1 blocker users to non-users among patients hospitalized for acute respiratory distress or pneumonia.